PXS Stock Chart & Stats
€0.09
€0.01(5.22%)
At close: 4:00 PM EST
€0.09
€0.01(5.22%)
Day’s Range― - ―
52-Week Range€0.06 - €0.17
Previous CloseN/A
Volume0.00
Average Volume (3M)133.00
Market Cap
€150.64M
Enterprise Value€588.69M
Total Cash (Recent Filing)€23.68M
Total Debt (Recent Filing)€388.90M
Price to Earnings (P/E)―
Beta0.28
Next Earnings
Mar 04, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,655,305,400
10 Day Avg. Volume0
30 Day Avg. Volume133
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.76
Price to Sales (P/S)0.06
P/FCF Ratio-150.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€0.14Price Target Upside59.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.01
Revenue Forecast (FY)€2.37B
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRapid revenue growth indicates that Paragon Care is expanding its sales across healthcare and laboratory customers. If maintained, this larger revenue base can improve operating leverage, deepen supplier relationships, and provide a platform for restoring profitability as scale increases.
Operating Cash Flow ReboundThe return to positive operating cash flow shows that the business generated cash from its core operations in 2026 despite weak reported earnings. This supports day-to-day funding capacity and offers a basis for improving financial flexibility if cash conversion becomes more consistent.
Integrated Healthcare Distribution ModelCombining product distribution with consumables and technical services gives Paragon Care multiple revenue streams around healthcare workflows. Installed equipment can support follow-on demand, while service capabilities may strengthen customer relationships and make the offering more valuable than product resale alone.
Bears Say
Severe Margin CompressionThe sharp decline in gross margin and near break-even EBIT show that strong sales growth is not currently translating into operating earnings. Persistently thin margins leave little room for cost inflation, pricing pressure, or adverse product mix and make recovery dependent on rebuilding profitability.
Return To Net LossesA return to losses weakens internal funding capacity and signals that recent growth has been accompanied by significant profitability pressure. Unless earnings recover, Paragon Care may have less ability to reinvest, reduce debt, or withstand further operating volatility over the coming periods.
Higher LeverageRising debt relative to equity increases financial risk while profitability is under pressure. Greater leverage can constrain capital allocation and amplify the effect of weak earnings, leaving less flexibility to fund expansion or absorb continued margin weakness without balance-sheet strain.
Paragon Care Limited News
PXS FAQ
What was Paragon Care Limited’s price range in the past 12 months?
Paragon Care Limited lowest stock price was €0.06 and its highest was €0.17 in the past 12 months.
What is Paragon Care Limited’s market cap?
Paragon Care Limited’s market cap is €150.64M.
When is Paragon Care Limited’s upcoming earnings report date?
Paragon Care Limited’s upcoming earnings report date is Mar 04, 2027 which is in 131 days.
How were Paragon Care Limited’s earnings last quarter?
Paragon Care Limited released its earnings results on Aug 25, 2026. The company reported €0.005 earnings per share for the quarter.
Is Paragon Care Limited overvalued?
According to Wall Street analysts Paragon Care Limited’s price is currently Undervalued.
Does Paragon Care Limited pay dividends?
Paragon Care Limited does not currently pay dividends.
What is Paragon Care Limited’s EPS estimate?
Paragon Care Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Paragon Care Limited have?
Paragon Care Limited has 1,655,305,400 shares outstanding.
What happened to Paragon Care Limited’s price movement after its last earnings report?
Paragon Care Limited reported an EPS of €0.005 in its last earnings report. Following the earnings report the stock price went up 2.857%.
Which hedge fund is a major shareholder of Paragon Care Limited?
Currently, no hedge funds are holding shares in DE:PXS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Paragon Care Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€0.14 (59.68% Upside)
€0.14 (59.68% Upside)
Blogger Sentiment
Bullish
DE:PXS Sentiment 100%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Fundamentals
Return on Equity
-5.34%
Trailing 12-Months
Asset Growth
20.99%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Paragon Care Limited
Paragon Care Limited distributes medical equipment, devices, and consumable products in Australia, New Zealand, and Asia. The company designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohematology laboratories; offers ophthalmology and optometry, neonatal vision screening solutions, and procedural kits. It also provides neonatal and paediatric assessment, including newborn hearing and vision screening, jaundice management, NICU video monitoring, brain monitoring, breast milk tracking, electrodes; sterilisable transducers designed for surgical procedures, digital theatre integration, infection control, infusion therapy, temperature management, enteral feeding, pain management, lasers, operating room products, surgical consumables, and ultrasound systems. In addition, the company offers aesthetic devices for dermatologists, cosmetic surgeons, general practitioners, beauty and aesthetic providers, and educational institutions; natural, traditional, and complementary health products and services; critical care and dental solutions; urology solutions, such as shockwave therapy, lasers, and accessories for infection control; medical products and consumables; and orthopaedics solutions, including hip and knee arthroplasty, upper and lower extremity, sports medicine, reverse shoulder replacement, and powered surgical tools. Further, it offers medical equipment repair, maintenance, and support services; technology and communication solutions, such as telephony, nurse call, access control, cctv, cordless, and Wi-Fi; supplies medical equipment to veterans, war widows, and families; and veterinary products. Additionally, it is involved in maintenance of technical medical equipment to the health, aged care, and veterinary markets; and distribution of pharmaceuticals, medical consumables, and complementary medicines to Australian healthcare market. The company is based in Mount Waverley, Australia.
PXS Stock 12 Month Forecast
Average Price Target
€0.14
▲(59.68% Upside)
Technical Analysis
Sigma Healthcare Ltd
―
Polynovo
―
Compumedics Limited
―
Epsilon Healthcare Limited
―
Trajan Group Holdings Ltd
―